advertisement
Abstract #6831 Published in IGR 4-1
HLA-DR expression in conjunctival cells after latanoprost
Guglielminetti E; Barabino S; Monaco M; Mantero S; Rolando MJournal of Ocular Pharmacology and Therapeutics 2002; 18: 1-9
The purpose of this randomized, controlled, masked study was to evaluate the effects of latanoprost 0.005% (Xalatan®, Pharmacia and Upjohn, Milan, Italy) on the ocular surface in patients with ocular hypertension or primary open-angle glaucoma. The study group included 14 patients who underwent latanoprost 0.005% eye drops once a day in both eyes for four months. The control group underwent unpreserved substitute tears eye drops (Aquasalina®, Bruschettini, Genoa, Italy) with the same posology and the same concentration of benzalkonium chloride (0.02%). Patients were controlled at one, three, and four months for symptoms, intraocular pressure, corneal sensitivity (Cochet-Bonnet test) and fluorescein staining. At the same control times, they underwent impression cytology and conjunctival brush cytology. Immunohistochemical techniques were used to detect HLA-DR expression in conjunctival cells. At each control, no significant statistical differences were found between the study and the control group, except for a higher expression of HLA-DR in the latanoprost group (p < 0.001). Since HLA-DR is a marker of ocular surface inflammation, this study suggests that a subclinical inflammatory reaction is present in the ocular surface of patients under latanoprost therapy. The pathway by which the inflammation is stimulated is yet unknown.
Dr. E. Guglielminetti, Clinica Oculistica, Universita di Genova, Osp. S. Martino, Pad. IX, 16132 Genova, Italy. elgugli@tin.it
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
